Nectar Lifesciences Limited has submitted the Exchange a copy Scrutinizers report of Extraordinary General Meeting held on August 04, 2025. Further, the company has informed the Exchange regarding voting results.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences held an EGM on August 4, 2025, where all three resolutions were passed with requisite majority. Resolution 1 approved the appointment of Dr. Surulichamy Senthilkumar as a Director liable to retire by rotation, passing with 98.70% of votes in favour (120.82 crore shares for vs. 1.59 crore against). Resolution 2 approved his appointment as Wholetime Director (R&D) for a period of three years, also passing with 98.70% support on similar voting. Resolution 3, a special resolution, approved the transfer of the company's business to Ceph Lifesciences Private Limited on a slump sale (going concern) basis, passing with 98.29% in favour (120.31 crore vs. 2.10 crore against) and also secured approval from the majority of public shareholders.
The appointment of a dedicated R&D Wholetime Director signals a focus on innovation and research-led growth. More significantly, the slump sale of the business to Ceph Lifesciences is a major restructuring event that could reshape the company's future operations and financial profile — investors should monitor for further disclosures on the deal valuation and strategic rationale.